Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Odrowaz Zaneta 2. Date of Event Requiring Statement (Month/Day/Year) 08/04/2026 3. Issuer Name and Ticker or Trading Symbol Attovia Therapeutics, Inc. [ATTO] (Last) (First) (Middle) C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Business Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SAN CARLOS, CA 94070 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 103,269(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	08/16/2033	Common Stock	15,137	$1.5793	D
Stock Option (Right to Buy)	(3)	03/05/2034	Common Stock	5,382	$2.8799	D
Stock Option (Right to Buy)	(4)	05/08/2034	Common Stock	102,260	$3.5302	D
Stock Option (Right to Buy)	(5)	05/17/2035	Common Stock	85,037	$4.9237	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Odrowaz Zaneta C/O ATTOVIA THERAPEUTICS, INC. 1091 INDUSTRIAL ROAD, SUITE 310 SAN CARLOS, CA 94070			Chief Business Officer

Signatures

/s/ Steven Chan, Attorney-in-Fact		08/04/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	As of the date of this Form 3, 17,156 shares are unvested. The remaining shares will continue to vest monthly and will be fully vested on April 27, 2027, subject to continued service to the Issuer through each vesting period.
(2)	The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on August 17, 2024, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
(3)	The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on March 6, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
(4)	The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 9, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
(5)	The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 18, 2026, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.